InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,551.21
(
-0.53%
)
Post# of 251714
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

lgonber

Send PM Follow Ignore
Followers 12
Posts 648
Boards Moderated 0
Alias Born 12/20/2014

lgonber

Re: None

Thursday, 01/16/2020 8:15:45 AM

Thursday, January 16, 2020 8:15:45 AM

Post# of 251714
TG Therapeutics (NASDAQ:TGTX) launches its rolling New Drug Application (NDA) in the U.S. seeking accelerated approval for umbralisib for patients with previously treated marginal zone lymphoma (MZL) and follicular lymphoma (FL). It expects to complete the filing in H1.

“We are extremely pleased to have initiated our first NDA submission for umbralisib and to have received guidance from the FDA to include both MZL and FL in a single NDA."
Currently stock is at 52 wh
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up